BAFF
- Known as:
- BAFF
- Catalog number:
- CYT-307
- Product Quantity:
- 5µg
- Category:
- -
- Supplier:
- Prospecbio
- Gene target:
- BAFF
Related genes to: BAFF
- Gene:
- TNFRSF13C NIH gene
- Name:
- TNF receptor superfamily member 13C
- Previous symbol:
- -
- Synonyms:
- BAFFR, CD268
- Chromosome:
- 22q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2002-05-22
- Date modifiied:
- 2019-04-23
- Gene:
- TNFSF13B NIH gene
- Name:
- TNF superfamily member 13b
- Previous symbol:
- TNFSF20
- Synonyms:
- BAFF, THANK, BLYS, TALL-1, TALL1, CD257
- Chromosome:
- 13q33.3
- Locus Type:
- gene with protein product
- Date approved:
- 1999-07-19
- Date modifiied:
- 2018-11-22
Related products to: BAFF
Related articles to: BAFF
- Given that the proteome is a major source of therapeutic targets, we conducted a proteome-wide Mendelian randomization (MR) combined with transcriptome sequencing analysis to identify candidate protein markers and therapeutic targets for vitiligo. - Source: PubMed
Publication date: 2025/06/19
Yan ChenjueJiang LingHu YiboYou TingChen JingWu Songjiang - Bullous pemphigoid (BP) is an autoimmune blistering disease primarily affecting older individuals. B-cell activating factor (BAFF), a member of the tumor necrosis factor superfamily, is crucial for B cell survival and T cell function. However, its role in the development of BP remains unclear. - Source: PubMed
Publication date: 2025/04/15
Li LiangFang HuiShen ShengxianLi KangLi ZhiguoMiao HaijunLi XiaShao ShuaiDang ErleWang GangQiao Hongjiang - Systemic lupus erythematosus is a chronic, multisystemic, inflammatory disease. Aquaporins, a group of transmembrane channels, are known to help prime immune cells and their migration. In this study, a qRT-PCR analysis was performed to identify aquaporins whose expression in SLE patients was associated with the inflammatory profile of B cells. - Source: PubMed
Publication date: 2025/05/06
Baharlooi HusseinEnayati SamanehAhmadzadeh NooshinMadreseh ElhamFaezi Seyedeh TaherehAlikhani MajidJamshidi AhmadrezaMahmoudi MahdiFarhadi Elham - B-cell activating factor belonging to the TNF family (BAFF), also known as B-lymphocyte stimulator (BLyS), plays a crucial role in B-cell development. It has multiple receptors, including BCMA, TACI, and BAFF-R, with diverse roles in different cell types. BAFF induces B-cell proliferation and immunoglobulin secretion, and acts as a survival factor for immature, naive, and activated B cells. Consequently, BAFF-deficient mice often show suppressed humoral responses, while BAFF-overexpressing mice show the higher number of mature B cells and may develop autoimmune-like manifestations and B-cell lymphoproliferative diseases. Elevated BAFF levels are also associated with various hematological malignancies, and its expression correlates with disease progression in some cases. Therefore, BAFF-targeted therapies, such as belimumab, atacicept, and tabalumab, are being explored in clinical trials for conditions like chronic lymphocytic leukemia (CLL) and multiple myeloma. Belimumab, an anti-BAFF monoclonal antibody, is being investigated in combination with rituximab/venetoclax for CLL. Atacicept, a decoy receptor for BAFF and APRIL, showed tolerability in a phase 1b trial for CLL. Tabalumab, another monoclonal antibody targeting BAFF, did not demonstrate significant efficacy in a phase 2 study for relapsed/refractory multiple myeloma. BAFF ligand-based CAR-T cells are designed to target BAFF receptors and show promise in preclinical studies, particularly for B-cell malignancies. The review emphasizes the importance of understanding the roles of BAFF and its receptors in the microenvironment of hematologic malignancies. Targeting BAFF and its receptors presents potential therapeutic avenues, and ongoing clinical trials provide valuable insights. - Source: PubMed
Publication date: 2024/09/02
Tagami NamiYuda JunichiroGoto Yasuyuki - BAFF, a vital B cell survival and differentiation factor, has three receptors: B-cell maturation antigen (BCMA), transmembrane activator and CAML interactor (TACI) and BR3. Although B cells are greatly reduced in B6.Baff (which harbour no BAFF) and B6.Br3 mice (which harbour supra-normal levels of BAFF), the distributions of B cell subsets and relationships between Foxp3 and CD4 cells in these mice differ. Using a large panel of B6 congenic knockout and/or transgenic mice, we demonstrate that (1) supra-normal levels of BAFF per se do not explain the phenotypic differences between B6.Baff and B6.Br3 mice; (2) B cells are expanded in B6.Taci mice, with preferential expansion of follicular (FO) B cells at the expense of CD19CD21CD23 B cells but without the preferential expansion of Foxp3 cells observed in B6 mice bearing a Baff transgene; (3) despite no expansion in total B cells, percentages of FO B cells and marginal zone B cells are higher and percentages of CD19CD21CD23 B cells are lower in young B6.Bcma mice, consistent with the inability of B6.Br3.Taci mice to recapitulate the B cell profile of B6.Baff mice; and (4) percentages of Foxp3 cells in B6.Br3.Taci mice are intermediate between those in B6.Br3 and B6.Taci mice despite the B cell profile of B6.Br3.Taci mice strongly resembling that of B6.Br3 mice. Collectively, our findings point to a non-redundant role for each of the BAFF receptors in determining the ultimate lymphocyte profile of the host. This may have clinically relevant ramifications in that the degree that a candidate therapeutic agent blocks engagement of any given individual BAFF receptor may affect its clinical utility. - Source: PubMed
Publication date: 2024/08/31
Stohl WilliamWu YingStohl Malka